Gilder Gagnon Howe & Co’s Revance Therapeutics, Inc. RVNC Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-57,123	Closed	-$1.45M	–	315
2023 Q2	$1.45M	Buy	57,123 +1,606	+3%	+$50K	0.02%	213
2023 Q1	$1.79M	Buy	55,517 +2,578	+5%	+$80.4K	0.03%	177
2022 Q4	$977K	Sell	52,939 -3	-0%	-$69	0.02%	198
2022 Q3	$1.43M	Buy	+52,942	New	+$1.07M	0.02%	186

Other funds holding RVNC

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Gilder Gagnon Howe & Co's RVNC Position: Q3 2023 in Review

Gilder Gagnon Howe & Co sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2023, closing a stake of 57,123 shares — an estimated $1.45M sold.

Gilder Gagnon Howe & Co first reported a position in RVNC in Q3 2022 and held it in 4 quarters. The position peaked at $1.79M in Q1 2023. 186 funds tracked by Wall St. Rank hold RVNC as of Q3 2023.

Gilder Gagnon Howe & Co reported no remaining Revance Therapeutics, Inc. position as of Q3 2023 after selling out during the quarter.
Gilder Gagnon Howe & Co sold 57,123 Revance Therapeutics, Inc. shares in Q3 2023, an estimated $1.45M.
Gilder Gagnon Howe & Co first reported a position in Revance Therapeutics, Inc. in Q3 2022 and held it in 4 quarters.
Gilder Gagnon Howe & Co's Revance Therapeutics, Inc. position peaked at $1.79M in Q1 2023.
186 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2023.

Based on Gilder Gagnon Howe & Co's 13F filing for Q3 2023, filed 14 Nov 2023.